FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer By Ogkologos - January 17, 2025 760 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ADRIATIC study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR Studying “Total Diet” and Its Impact on Health, Including Cancer Risk October 25, 2018 ESMO Joins the European Health Alliance on Alcohol (EHAA) Seeking to... August 14, 2025 EMA Recommends Granting a Marketing Authorisation for Lutetium (177lu) Chloride August 4, 2022 EMA Recommends Extension of Indications for Trastuzumab Deruxtecan to Include Treatment... March 21, 2025 Load more HOT NEWS Majority of Patients With Cancer Are Willing To Be Vaccinated Against... How to Stay Connected When Your Partner Has Cancer Addressing Mental Health Needs of Adolescent and Young Adult Cancer Survivors Phlebotomist Breaks Into Ballet Performance In The Middle Of The Hospital
